Routine SARS-CoV-2 vaccination for all children.
| Autor: | De Paris K; Department of Microbiology and Immunology, Center for AIDS Research, and Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Permar SR; Department of Pediatrics, Weill Cornell Medicine/ New York Presbyterian, New York, New York, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Immunological reviews [Immunol Rev] 2022 Aug; Vol. 309 (1), pp. 90-96. Date of Electronic Publication: 2022 Jul 07. |
| DOI: | 10.1111/imr.13108 |
| Abstrakt: | The SARS-CoV-2 pandemic has resulted in unprecedented health and economic losses. Children generally present with less severe disease from this virus compared with adults, yet neonates and children with COVID-19 can require hospitalization, and older children can develop severe complications, such as the multisystem inflammatory syndrome, resulting in >1500 deaths in children from COVID-19 since the onset of the pandemic. The introduction of effective SARS-CoV-2 vaccines in school-age children and adult populations combined with the emergence of new, more highly transmissible SARS-CoV-2 variants has resulted in a proportional increase of infections in young children. Here, we discuss (1) the current knowledge on pediatric SARS-CoV-2 infection and pathogenesis in comparison with adults, (2) the data on vaccine immunogenicity and efficacy in children, and (3) the benefits of early life SARS-CoV-2 vaccination. (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|